We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.
- Authors
Gerdes, Lisa Ann; Held, Kathrin; Beltrán, Eduardo; Berking, Carola; Prinz, Jörg C.; Junker, Andreas; Tietze, Julia K.; Ertl‐Wagner, Birgit; Straube, Andreas; Kümpfel, Tania; Dornmair, Klaus; Hohlfeld, Reinhard
- Abstract
We investigated a patient who developed multiple sclerosis (MS) during treatment with the CTLA4-blocking antibody ipilimumab for metastatic melanoma. Initially he showed subclinical magnetic resonance imaging (MRI) changes (radiologically isolated syndrome). Two courses of ipilimumab were each followed by a clinical episode of MS, 1 of which was accompanied by a massive increase of MRI activity. Brain biopsy confirmed active, T-cell type MS. Quantitative next generation sequencing of T-cell receptor genes revealed distinct oligoclonal CD4(+) and CD8(+) T-cell repertoires in the primary melanoma and cerebrospinal fluid. Our results pinpoint the coinhibitory molecule CTLA4 as an immunological checkpoint and therapeutic target in MS. Ann Neurol 2016;80:294-300.
- Publication
Annals of Neurology, 2016, Vol 80, Issue 2, p294
- ISSN
0364-5134
- Publication type
journal article
- DOI
10.1002/ana.24715